Your session is about to expire
← Back to Search
Drug Resistance Research for Osteosarcoma
N/A
Waitlist Available
Led By John Healey, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients with a presumed or known diagnosis of a primary or secondary bone cancer or other solid tumor who are having or have had a biopsy or surgery to remove tumor for diagnostic or therapeutic reasons. No tumors will be obtained solely for research purposes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Summary
This trial will study how different drugs affect tumors and why some tumors develop high pressure, which can affect how well drugs work. Blood samples will be taken to help predict the behavior of different types of tumors.
Who is the study for?
This trial is for individuals with a presumed or confirmed diagnosis of bone cancer (osteosarcoma) or other solid tumors who are undergoing biopsy or surgery. It's open to adults and minors; adults must consent, while minors give assent and have parental consent.Check my eligibility
What is being tested?
The study aims to understand how osteogenic sarcoma and other solid tumors react to drug therapies by examining tumor tissue and blood samples. Researchers will look into why some tumors resist treatment and the impact of internal tumor pressure on drug effectiveness.See study design
What are the potential side effects?
Since this trial involves tissue procurement rather than testing a new medication, there aren't direct side effects from drugs being studied. However, typical risks associated with biopsies or surgeries may apply.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have or had a biopsy or surgery for bone or solid tumor cancer diagnosis or treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To test tumor samples obtained from patients with primary or secondary bone cancer for mechanisms of acquired and intrinsic resistance to methotrexate and to relate these findings to histologic response to preoperative chemotherapy and outcome.
Secondary outcome measures
To attempt to grow these tumor cells in short term culture to test the sensitivity of these cells to chemotherapeutic agents and to correlate cytotoxicity with biochemical and molecular studies.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Hospital for Special Surgery, New YorkOTHER
246 Previous Clinical Trials
58,841 Total Patients Enrolled
Weill Medical College of Cornell UniversityOTHER
1,064 Previous Clinical Trials
1,318,423 Total Patients Enrolled
Columbia UniversityOTHER
1,448 Previous Clinical Trials
2,530,727 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger